Why Gynecological Cancers Remain Taboo—and Why the Words We Choose Matter
By Dr. Gabrijela Sopta
Department of Gynecology and Obstetrics, Clinical Hospital Center Rijeka, Croatia
Introduction
Medicine has entered an era of extraordinary scientific progress. Over the past two decades, gynaecologic oncology has witnessed remarkable advances in minimally invasive surgery, molecular pathology, genomic profiling, targeted therapies, immunotherapy, and personalised cancer care. Diseases that were once uniformly fatal are increasingly becoming chronic conditions, while screening programmes and HPV vaccination offer an unprecedented opportunity to prevent thousands of cancers before they even develop. From a scientific perspective, we have never understood gynaecological malignancies better than we do today.
Yet every day, in clinics and operating theatres around the world, another reality unfolds—one that cannot be explained by molecular biology, imaging technologies or clinical guidelines.
Women continue to arrive with advanced disease after months, and sometimes years, of unexplained symptoms. Many apologise before describing abnormal vaginal bleeding. Others lower their voices when mentioning persistent bloating, pelvic pain, changes in sexual function or vulval discomfort. Some admit that they searched the internet for weeks before finding the courage to book an appointment. Others tell us they spoke to nobody—not their partner, not their family, not even their closest friends.
As gynaecological oncologists, we often ask ourselves why.
Why, despite unprecedented access to medical information, do so many women still delay seeking help?
Why do cancers affecting half of the world’s population remain surrounded by silence?
The answer extends far beyond medicine.
The greatest challenge facing women with gynaecological cancers is not always the biology of the disease itself. Often, it is the invisible burden carried long before diagnosis—a burden shaped by culture, tradition, gender expectations, misconceptions and stigma.
Unlike many other malignancies, gynaecological cancers arise in organs intrinsically linked to identity. The uterus is associated with motherhood. The ovaries symbolise fertility. The cervix has long been intertwined with discussions surrounding sexuality, while diseases affecting the vulva or vagina continue to be regarded as deeply private, sometimes even shameful. These organs are not perceived solely through their biological function. They carry profound emotional, social and cultural meaning.
Consequently, women diagnosed with gynaecological cancer frequently experience two illnesses simultaneously.
The first is cancer.
The second is silence.
Although invisible on CT scans or pathology reports, this silence influences nearly every stage of the patient’s journey—from symptom recognition and healthcare-seeking behaviour to treatment adherence, quality of life and survivorship. Increasing evidence demonstrates that cancer-related stigma is associated with delayed presentation, greater psychological distress, poorer communication with healthcare professionals and reduced engagement with healthcare systems. These are not merely psychosocial concerns; they are determinants of health outcomes that deserve the same attention as tumour biology and therapeutic innovation.
The paradox is striking. We invest enormous resources into developing increasingly sophisticated treatments, while paying comparatively little attention to one of the most accessible therapeutic tools available to every clinician: communication.
Words matter.
They shape how women interpret symptoms.
They influence whether a patient feels safe enough to ask a difficult question.
They determine whether a diagnosis becomes a source of empowerment or isolation.
They affect how families cope, how society perceives disease, and ultimately how healthcare is delivered.
Scientific progress has transformed the management of gynaecological cancers. Communication, however, has not evolved at the same pace.
As clinicians, we are trained to interpret pathology reports, perform radical surgery and navigate complex treatment algorithms. Far less time is devoted to understanding how language itself influences health behaviour. Yet every consultation reminds us that medicine is practiced not only through scalpels, imaging and pharmaceuticals, but also through conversation.
Patients rarely remember every statistic we present. They often forget percentages, drug names or details of treatment protocols.
They remember something else.
They remember whether they felt respected.
Whether they felt judged.
Whether someone looked them in the eye when discussing fertility.
Whether anyone acknowledged their fears about intimacy after treatment.
Whether the physician sitting opposite them recognised not merely a diagnosis, but a woman whose identity extends far beyond her disease.
This is where modern oncology must continue to evolve.
The future of gynaecological oncology will undoubtedly be driven by artificial intelligence, molecular diagnostics and precision medicine. Yet genuine progress cannot be measured solely by improved survival curves. It must also be reflected in our ability to create healthcare environments in which women feel heard, understood and free from judgement.
Breaking the silence surrounding gynaecological cancers is therefore not simply a communication strategy.
It is a clinical responsibility.
Because while cancer begins within cells, stigma begins with words.
And words, when chosen carefully, possess extraordinary power—not only to inform, but also to heal.
The Anatomy of Silence
Every disease carries a biological burden. Gynaecological cancers carry an additional one—a burden of silence.
Unlike cancers affecting organs that society discusses more openly, malignancies of the uterus, ovaries, cervix, vulva and vagina develop within anatomical sites that have, for centuries, been surrounded by privacy, modesty and, in many cultures, shame. Although these organs are fundamental to human life, reproduction and identity, conversations about them often remain confined to whispered discussions, avoided entirely, or replaced by euphemisms.
This cultural silence begins long before a woman ever enters a hospital.
Across many societies, girls grow up learning that menstruation should remain discreet. Conversations about sexuality are frequently uncomfortable, while menopause is often portrayed as the quiet conclusion of a woman’s reproductive life rather than a natural biological transition. Even in countries with highly developed healthcare systems, reproductive health is still discussed less openly than many other aspects of medicine.
It is therefore unsurprising that cancers affecting these organs inherit the same silence.
As clinicians, we witness its consequences every day.
Women frequently apologise before describing symptoms that should never require an apology.
“I’m sorry if this sounds embarrassing…”
“I wasn’t sure if I should mention it…”
“I thought it was probably nothing.”
“I didn’t want to waste anyone’s time.”
These are not isolated observations. They are recurring conversations that unfold in outpatient clinics across the world.
Abnormal uterine bleeding is one of the earliest warning signs of endometrial cancer, yet many women attribute it to stress, menopause or hormonal fluctuations. Persistent abdominal bloating—a symptom classically associated with ovarian cancer—is commonly dismissed as dietary intolerance or digestive discomfort. Vulvar itching or chronic irritation may be self-treated for months with over-the-counter creams before specialist evaluation is sought.
By the time some women arrive in our clinics, they have been living with symptoms for months.
Sometimes for years.
Importantly, these delays rarely arise from ignorance alone.
They arise because many symptoms involve body parts that society has taught women not to discuss openly.
Scientific literature increasingly recognises that cancer-related stigma is not merely a social inconvenience; it represents a measurable barrier to healthcare. Women experiencing shame, embarrassment or fear of judgement are more likely to postpone medical consultation, less likely to disclose sensitive symptoms and more vulnerable to psychological distress following diagnosis.¹ These findings are consistent across different healthcare systems and cultural backgrounds, suggesting that stigma is not restricted to individual societies but represents a global challenge.
Perhaps nowhere is this more evident than in cervical cancer.
Although persistent infection with high-risk human papillomavirus (HPV) is now recognised as a necessary cause of nearly all cervical cancers, misconceptions remain widespread. HPV is one of the most common viral infections worldwide, affecting the majority of sexually active individuals during their lifetime. Yet many women continue to associate an HPV diagnosis with guilt, promiscuity or personal failure.
As physicians, we know this perception is scientifically unfounded.
As clinicians, however, we also know that science alone does not erase shame.
The emotional burden carried by women diagnosed with HPV-related disease often reflects society’s interpretation of the infection rather than its biological reality.
This distinction matters.
Because patients do not experience disease through pathology reports alone.
They experience disease through the lens of culture.
The same applies to ovarian cancer.
Unlike cervical or endometrial cancer, ovarian cancer frequently develops silently, with symptoms that are vague and easily attributed to benign conditions. Women often describe feeling guilty after diagnosis, believing they “should have noticed earlier.” Families ask why the disease was not discovered sooner. Physicians explain the biological complexity of early detection.
Behind every conversation lies the same painful misconception—that delayed diagnosis necessarily reflects personal failure.
It does not.
Modern oncology must continue to communicate this message with clarity and compassion.
Cancer is not a consequence of insufficient awareness, poor character or inadequate resilience.
Nor is it a punishment.
Yet despite overwhelming scientific evidence supporting these facts, stigma continues to influence how women perceive themselves following diagnosis.
Many patients tell us they no longer recognise their own bodies.
Following radical surgery, chemotherapy or pelvic radiotherapy, women frequently describe feelings of loss that extend beyond physical symptoms. The uterus, ovaries or vulva are not merely anatomical structures removed during an operation. For many, they represent fertility, intimacy, femininity and identity.
Medicine often measures successful treatment through survival statistics.
Patients measure success differently.
Can I still feel like myself?
Will my partner still find me attractive?
Can I become a mother?
Will intimacy ever feel normal again?
These questions are rarely visible within clinical guidelines.
Yet they are among the most important questions our patients ask.
Perhaps the greatest paradox of modern gynaecological oncology is this:
While we have become exceptionally skilled at treating tumours, we remain less comfortable addressing the emotional consequences of diseases affecting intimate organs.
And yet, these conversations are inseparable from high-quality cancer care.
If our goal is truly patient-centred medicine, then we must recognise that stigma is not an abstract sociological concept. It is a clinical reality encountered every day—in delayed diagnoses, in unasked questions, in hidden fears and in the silence that too often fills consultation rooms.
Breaking that silence begins not with new technology, but with something far more fundamental.
It begins by creating an environment in which every woman feels that no symptom is too embarrassing to mention, no fear too insignificant to express and no question too difficult to ask.
Because the opposite of stigma is not simply awareness.
It is trust.
When Language Becomes a Determinant of Health
Medicine is often described as a science. Increasingly, however, it is recognised that medicine is equally a language.
Every diagnosis begins with words.
Every treatment decision is explained through words.
Every prognosis, every difficult conversation, every moment of hope or uncertainty is carried by language.
For decades, oncology has focused on understanding how genetics, tumour biology and the immune system influence clinical outcomes. Yet a growing body of evidence suggests that another determinant of health has received comparatively little attention: the way we communicate with our patients. Language is not simply a vehicle through which information is delivered. It actively shapes how patients perceive illness, how they respond to treatment, how much they trust their physicians and, ultimately, whether they engage with healthcare at all.²
As clinicians, we often underestimate the power of the words we choose.
A consultation may last twenty or thirty minutes.
The patient may remember only a handful of sentences.
Those sentences can stay with her for years.
I have often reflected that patients rarely quote survival statistics when they return for follow-up. They do not remember the exact percentage of recurrence risk or the details of a molecular classification. What they remember is a sentence.
“We’re going to face this together.”
“You came at the right time.”
“You still have options.”
Or, unfortunately:
“There is nothing more we can do.”
The intention behind these words may be identical, yet their impact is profoundly different.
Communication is not simply about accuracy.
It is about meaning.
This is particularly true in gynaecological oncology, where language intersects with identity, sexuality and deeply personal aspects of life. A diagnosis involving the uterus, cervix, ovaries or vulva is rarely experienced as affecting a single organ. For many women, it touches their perception of womanhood, fertility, intimacy and self-worth.
Consequently, the language surrounding these diseases carries emotional weight that extends far beyond medical terminology.
Consider, for example, how frequently women diagnosed with cervical cancer ask whether they somehow “caused” their disease.
Despite decades of scientific evidence demonstrating that persistent infection with high-risk human papillomavirus is extraordinarily common, misconceptions remain deeply embedded within society. Many patients arrive already carrying feelings of guilt before a physician has spoken a single word.
If we respond only with scientific facts, we may answer the question.
If we respond with empathy, we address the fear behind the question.
There is an important difference.
Communication is not merely the transfer of knowledge.
It is the recognition of emotion.
The same principle applies throughout the cancer journey.
When discussing surgery, we often describe procedures using technical language: radical hysterectomy, bilateral salpingo-oophorectomy, lymphadenectomy, pelvic exenteration.
These terms are precise and necessary.
But to the woman sitting across from us, they translate into different questions.
“Will I still be able to have children?”
“Will menopause begin tomorrow?”
“Will I still feel like myself?”
“Will intimacy become painful?”
“Will my partner look at me differently?”
These questions rarely appear in surgical textbooks.
Yet they are among the most clinically relevant questions we encounter.
Evidence from psycho-oncology consistently demonstrates that compassionate, patient-centred communication reduces anxiety, improves satisfaction with care, strengthens therapeutic alliance and facilitates shared decision-making.³ Patients who feel listened to are more likely to disclose symptoms, adhere to treatment recommendations and remain engaged throughout survivorship. Communication, therefore, should not be regarded as an optional skill or an expression of individual personality. It is a core clinical competency.
Perhaps one of the greatest misconceptions in medicine is that empathy and scientific excellence exist at opposite ends of a spectrum.
They do not.
The most accomplished clinicians are rarely those who simply possess exceptional technical ability.
They are those who combine scientific rigour with human understanding.
In the operating theatre, our responsibility is precision.
In the consultation room, our responsibility is presence.
One does not replace the other.
Both save lives.
This understanding has become increasingly important as oncology enters the era of precision medicine. Molecular classifications, artificial intelligence and personalised therapies continue to redefine clinical practice. Yet none of these innovations can replace the trust established during a conversation between physician and patient.
Technology may improve treatment.
Language determines whether patients feel able to receive it.
For this reason, I believe communication should be recognised not merely as a professional skill, but as a therapeutic intervention in its own right.
Just as we carefully select a chemotherapy regimen according to tumour biology, we should choose our words with equal precision and care.
Because words can reduce fear.
Words can restore dignity.
Words can encourage a woman to return when symptoms recur rather than suffering in silence.
And sometimes, long after the details of surgery or chemotherapy have faded from memory, words remain the most enduring part of treatment.
If modern oncology truly aspires to deliver personalised care, then personalised communication must become part of that vision.
Not because it makes us kinder physicians.
But because it makes us better physicians.
Beyond Survival: What We Rarely Measure
For much of modern oncology, success has been defined by numbers.
Overall survival.
Disease-free survival.
Progression-free survival.
Hazard ratios.
Recurrence rates.
These endpoints have transformed cancer care and remain fundamental to evaluating treatment efficacy. They guide clinical decisions, shape international guidelines and determine the therapies we offer our patients. Without them, progress in oncology would not have been possible.
Yet there is an important question that survival curves cannot answer.
What kind of life awaits the woman who survives?
As gynaecological oncologists, we celebrate every patient who completes treatment, every normal follow-up examination and every reassuring imaging report. These are moments worth celebrating. But they are not the end of the story.
For our patients, survivorship is not a single milestone.
It is the beginning of a new life.
Increasingly, women survive gynaecological cancers for many years, even decades. This remarkable achievement reflects advances in surgery, systemic therapy and multidisciplinary care. However, it has also revealed a new responsibility.
Our role no longer ends when treatment is completed.
It evolves.
The woman leaving the oncology clinic is not simply a survivor. She is returning to her family, her career, her relationships and the everyday realities that cancer has profoundly altered.
Many of these changes remain invisible.
The scars heal.
Laboratory values return to normal.
CT scans become reassuring.
Yet beneath these visible signs of recovery, another process quietly unfolds.
A woman who undergoes bilateral oophorectomy at the age of thirty-eight does not experience only the loss of ovarian function. Overnight, she enters premature menopause. Vasomotor symptoms, sleep disturbance, sexual dysfunction, cognitive changes and accelerated bone loss become part of her daily reality. At precisely the moment society expects her to celebrate being cancer-free, she may be grieving a body that no longer feels familiar.
Another woman, treated successfully for cervical cancer, may hesitate to resume intimacy because she fears pain, bleeding or rejection. A patient recovering from vulvar cancer surgery may avoid looking at her own body for months. Others struggle with persistent lymphoedema, altered body image or chronic fatigue that continues long after chemotherapy has ended.
None of these experiences appear in pathology reports.
Yet every one of them influences quality of life.
Perhaps the most striking lesson I have learned from my patients is that healing and recovery are not synonymous.
A wound may heal.
Recovery takes much longer.
Sometimes years.
Sometimes a lifetime.
One conversation, in particular, has remained with me.
A patient, months after completing treatment, looked at me and said:
“Doctor, everyone keeps telling me how lucky I am because I survived. But nobody asks me how I am living.”
Her words captured a reality that clinical trials rarely measure.
Medicine has become increasingly successful at adding years to life.
We must now become equally committed to adding life to those years.
Quality of life is no longer a secondary outcome.
It is a fundamental outcome.
This philosophy has gradually become embedded within modern oncology. International societies, including ESGO, ESMO and ASCO, increasingly emphasise survivorship care, fertility preservation, management of treatment-related toxicity, sexual health and psychosocial support as essential components of comprehensive cancer care. These are not optional extras reserved for specialised centres. They represent good oncology.
Because surviving cancer should never require abandoning one’s identity.
For women of reproductive age, fertility often represents one of the most emotionally complex aspects of treatment. Advances in fertility-sparing surgery have transformed the management of selected patients with cervical, endometrial and ovarian malignancies. Yet not every woman is eligible for conservative treatment, and even when fertility preservation is possible, uncertainty often remains.
As clinicians, we tend to focus on explaining procedures.
Patients often hear something different.
“Will I ever become a mother?”
There may be no more difficult question in gynaecological oncology.
Sometimes we can answer it with hope.
Sometimes we cannot.
In either situation, honesty and compassion are equally important.
The same is true for sexual health.
Despite overwhelming evidence that sexuality represents an essential dimension of wellbeing, discussions regarding intimacy remain surprisingly uncommon within routine oncological practice. Time constraints, discomfort or uncertainty may prevent clinicians from initiating these conversations, while patients often hesitate to ask.
The result is predictable.
Both sides remain silent.
And silence is frequently mistaken for absence of need.
It is not.
Women consistently report that they would welcome conversations about sexual function, menopausal symptoms and body image if healthcare professionals initiated them in a respectful and informed manner. In other words, patients are not avoiding these discussions because they are unimportant.
They are waiting for permission to begin them.
This observation reminds us of a simple yet profound truth.
Communication itself is an intervention.
Sometimes the most therapeutic sentence a physician can offer is not an explanation of molecular pathways or treatment algorithms.
Sometimes it is simply:
“Many women experience this after treatment. You are not alone.”
Those seven words may not appear in any clinical guideline.
Yet they often become the beginning of healing.
Perhaps this is where modern gynaecological oncology must continue to evolve.
For decades, our mission has rightly been to reduce mortality.
Our next mission should be to restore wholeness.
Because a woman cured of cancer deserves more than the absence of disease.
She deserves the opportunity to reclaim her confidence, her relationships, her sexuality, her ambitions and her future.
She deserves not only to survive.
She deserves to live.
The Physician’s Voice: Every Consultation Is an Opportunity to Challenge Stigma
There is a moment that precedes every diagnosis.
Before pathology confirms malignancy.
Before imaging defines disease extent.
Before treatment options are discussed.
There is a conversation.
As physicians, we often think of communication as something that accompanies medical care. In reality, communication is medical care. It is the first therapeutic intervention every patient receives, and perhaps the only intervention that accompanies every stage of the cancer journey—from the first consultation to survivorship, recurrence or end-of-life care.
In gynaecological oncology, this responsibility carries particular significance.
Our patients entrust us with conversations about the most intimate aspects of their lives. They speak about fertility, sexuality, menopause, relationships, body image and fears they may never have shared with another person. Long before they allow us to perform surgery, they must first trust us with their vulnerability.
Trust, however, is never automatic.
It is earned.
Every consultation offers a choice.
We can focus exclusively on the tumour.
Or we can treat the woman sitting in front of us.
The distinction may appear subtle.
In practice, it changes everything.
As surgeons and oncologists, we spend years learning anatomy, refining surgical technique and mastering increasingly complex treatment algorithms. We are trained to interpret imaging, understand molecular pathways and make evidence-based decisions under pressure.
Yet comparatively little attention is devoted to one of the most powerful instruments available to every clinician.
Our voice.
Not because communication is less important.
But because its impact is more difficult to measure.
There is no biomarker for trust.
No laboratory value for compassion.
No imaging modality capable of demonstrating whether a woman leaves the consultation feeling reassured—or completely alone.
Nevertheless, these outcomes influence every aspect of care.
Patients who trust their physicians are more likely to disclose symptoms they initially considered embarrassing. They are more willing to discuss sexual difficulties, menopausal symptoms, urinary dysfunction or concerns about fertility. They ask questions they might otherwise suppress. They return earlier when new symptoms appear. They participate more confidently in shared decision-making.
In other words, trust changes behaviour.
And behaviour changes outcomes.
This understanding challenges a long-standing misconception in medicine—that empathy is an innate personality trait rather than a professional competence.
Empathy is not simply kindness.
It is a clinical skill.
It requires listening before explaining.
Curiosity before assumptions.
Presence before reassurance.
Perhaps the most important lesson our patients teach us is that silence rarely means absence of concern.
Often, it means the opposite.
The patient who says little may be carrying the greatest fear.
The woman who nods throughout the consultation may have understood very little.
The patient who insists that she is “fine” may simply believe that her concerns are inappropriate or insignificant.
These moments require more than medical expertise.
They require attention.
Sometimes, a single question changes the entire consultation.
“What worries you the most today?”
“What is the biggest change cancer has brought into your life?”
“Is there something you wanted to ask but found difficult to mention?”
These questions take seconds.
Their impact may last for years.
Increasingly, international organisations advocate for communication training as an integral component of oncology education. This reflects a broader recognition that patient-centred communication improves not only satisfaction with care, but also psychological wellbeing, treatment adherence and overall quality of care. Communication is gradually being recognised not as an optional “soft skill,” but as a measurable determinant of clinical excellence.
And yet, there remains another responsibility that extends beyond individual consultations.
As physicians, our words influence society.
Patients listen to us.
Families listen to us.
Journalists listen to us.
Students learn from us.
The language we use today becomes the language society adopts tomorrow.
When we speak openly about HPV without judgement, we reduce stigma.
When we discuss menopause after cancer as an expected and manageable consequence rather than an uncomfortable topic, we normalise survivorship.
When we acknowledge sexual health as an integral component of wellbeing, we legitimise conversations that many women have spent years avoiding.
Every public lecture.
Every media interview.
Every scientific presentation.
Every conversation with a medical student.
Every consultation.
Each represents an opportunity to reshape how society understands gynaecological cancers.
Perhaps this is one of the greatest privileges of our profession.
We do not simply treat disease.
We influence culture.
We challenge myths.
We replace fear with knowledge.
And, occasionally, we give women permission to speak about something they have carried in silence for far too long.
Ultimately, medicine is remembered not only for the operations we perform or the treatments we prescribe.
It is remembered for the way we make people feel at the moments they need us most.
Patients may never recall the exact details of a clinical guideline.
But they will remember whether they felt seen.
Whether they felt respected.
Whether they felt heard.
And whether, for the first time since their diagnosis, someone reminded them that they were more than their cancer.
Perhaps this is the true measure of excellence in modern gynaecological oncology.
Not only the ability to prolong life.
But the ability to preserve dignity while doing so.
Changing the Narrative: A Global Responsibility
Cancer is never experienced in isolation.
It unfolds within families, communities, healthcare systems and societies. Consequently, the stigma surrounding gynaecological cancers cannot be addressed solely within consultation rooms or operating theatres. It requires a broader transformation—one that extends into public health, education, media, policy and advocacy.
In recent decades, global oncology has demonstrated what is possible when science and advocacy move forward together.
Few examples illustrate this better than cervical cancer.
For the first time in history, humanity possesses the tools not merely to treat a cancer, but to eliminate it as a public health problem. Through HPV vaccination, organised screening programmes, early diagnosis and equitable access to treatment, the World Health Organization has set an ambitious but achievable goal: the elimination of cervical cancer within this century.¹⁰
This initiative represents far more than a vaccination strategy.
It is a statement that preventable suffering should no longer be accepted.
Yet elimination will not be achieved through vaccines and screening alone.
Women must feel sufficiently informed and empowered to participate in prevention programmes. Parents must feel confident discussing HPV vaccination with their children. Communities must understand that HPV is one of the most common human infections—not a reflection of morality, promiscuity or personal failure. Healthcare professionals must communicate these messages with clarity, consistency and compassion.
Without public trust, scientific progress cannot achieve its full potential.
This lesson extends beyond cervical cancer.
Across the spectrum of gynaecological malignancies, disparities remain profound. Access to specialised surgery, molecular diagnostics, genetic counselling, clinical trials and innovative therapies varies enormously between countries and, in many regions, even within the same healthcare system. Women living in rural areas, low-resource settings or socially disadvantaged communities often face additional barriers that compound the effects of stigma.
These inequalities remind us that the burden of cancer is never determined solely by tumour biology.
It is also shaped by geography.
Education.
Socioeconomic status.
Health literacy.
Gender equality.
Healthcare policy.
Addressing stigma therefore requires more than changing individual attitudes. It requires strengthening health systems capable of delivering equitable, evidence-based and person-centred care to every woman, regardless of where she lives.
Scientific societies have recognised this responsibility.
Organisations such as the European Society of Gynaecological Oncology (ESGO), the International Gynecologic Cancer Society (IGCS), the International Federation of Gynecology and Obstetrics (FIGO) and the European Society for Medical Oncology (ESMO) have increasingly expanded their focus beyond surgical excellence and therapeutic innovation. Contemporary guidelines now emphasise survivorship, shared decision-making, quality of life, fertility preservation, patient-reported outcomes and psychosocial support as integral components of high-quality cancer care.
This evolution reflects an important shift in philosophy.
Modern oncology is no longer defined solely by what we treat.
It is defined by how we care.
Equally transformative has been the growing role of patient advocacy organisations.
Over the past decade, patient advocates have fundamentally changed the conversation surrounding gynaecological cancers. They have challenged outdated misconceptions, encouraged women to recognise symptoms earlier, promoted participation in screening programmes and reminded healthcare professionals that lived experience represents a form of expertise in its own right.
Their voices have enriched medicine.
Not by replacing science.
But by humanising it.
Among these global initiatives, World GO Day occupies a unique position.
Its mission extends beyond raising awareness of gynaecological cancers. It seeks to create a worldwide community in which patients, clinicians, researchers, advocacy groups and policymakers work together toward a common goal: ensuring that no woman faces a gynaecological cancer alone or unheard.
Awareness campaigns are sometimes criticised as symbolic gestures.
When thoughtfully designed, they are anything but symbolic.
They change conversations.
They encourage women to seek help earlier.
They provide language where previously there was silence.
They remind survivors that their experiences matter.
And they challenge societies to confront diseases that have remained hidden for far too long.
As healthcare professionals, we should not underestimate the influence of our voices beyond the hospital walls.
Every scientific lecture contributes to education.
Every conference presentation shapes professional practice.
Every media interview has the potential to correct misinformation.
Every educational campaign may encourage one woman to recognise a symptom she might otherwise have ignored.
Public engagement is not separate from clinical care.
It is an extension of it.
Perhaps this is one of the defining responsibilities of modern physicians.
Our duty is no longer confined to diagnosing disease and prescribing treatment.
We are also educators.
Advocates.
Researchers.
Communicators.
And, increasingly, ambassadors for women’s health.
This responsibility carries particular significance in gynaecological oncology because the diseases we treat remain burdened by misconceptions that science alone cannot erase.
Evidence changes guidelines.
Conversations change culture.
Both are essential.
Ultimately, the future of gynaecological oncology will not be determined solely by technological innovation. It will also depend upon our willingness to build healthcare systems in which every woman feels informed, respected and empowered to seek care without fear or shame.
Because the elimination of stigma may prove to be one of the most important preventive strategies we have yet to fully embrace.
A Letter to Every Woman
If there is one message I hope every woman takes from these reflections, it is this:
Your body has never been something to apologise for.
Not when it menstruates.
Not when it changes during pregnancy.
Not when it enters menopause.
And certainly not when it becomes ill.
For far too long, women have been taught to minimise their symptoms, postpone medical appointments, endure pain in silence and place the needs of others before their own health.
Too many have convinced themselves that abnormal bleeding could wait.
That persistent bloating was probably stress.
That vulval discomfort was too embarrassing to mention.
That discussing intimacy after cancer somehow made them difficult patients.
It does not.
As physicians, we often tell our patients that early diagnosis saves lives.
This is true.
But before early diagnosis comes something even more fundamental.
The courage to speak.
If this article contributes, even in a small way, to making one woman feel less embarrassed about seeking help, then it has already achieved something meaningful.
Because silence has never protected women from cancer.
Conversation can.
To every woman reading these words:
Please never believe that your symptoms are insignificant.
Please never think you are wasting your doctor’s time.
Please never allow embarrassment to become a barrier between you and your health.
Your questions deserve answers.
Your fears deserve compassion.
Your experiences deserve to be heard.
As gynaecological oncologists, we have the privilege of meeting women during some of the most difficult moments of their lives.
They allow us into conversations that extend far beyond medicine.
They trust us with their fears about losing fertility before having children.
With worries about intimacy after surgery.
With concerns about their partners, families, careers and futures.
These conversations have changed the way I understand oncology.
They have reminded me that treating cancer is not simply about removing a tumour or prescribing the correct therapy.
It is about caring for the whole person.
Every woman who enters our clinic brings with her a unique story.
Some stories begin with hope.
Others begin with fear.
Many begin with silence.
Our responsibility is not only to diagnose disease.
It is to ensure that silence never becomes another burden our patients are forced to carry.
Scientific progress has transformed the outlook for women with gynaecological cancers.
Today we operate with greater precision than ever before.
We classify tumours according to their molecular profile.
We offer targeted therapies that would have seemed unimaginable only a generation ago.
We are moving steadily towards more personalised medicine.
These achievements deserve celebration.
But scientific excellence alone is not enough.
The future of gynaecological oncology will not be defined solely by innovation.
It will also be defined by empathy.
By communication.
By equity.
By our willingness to recognise that every pathology report belongs to a woman whose life cannot be summarised by a FIGO stage or a survival curve.
Perhaps that is the greatest lesson our patients teach us.
Cancer changes lives.
But so do kindness.
So does dignity.
So do words.
Because while cancer begins within cells, stigma begins with language.
And language—when guided by knowledge, compassion and humanity—has the extraordinary power not only to inform, but also to heal.
The conversation begins with us.
Let us ensure it never ends in silence.
Final Reflection
As clinicians, researchers and advocates, we often speak about changing the future of gynaecological cancer.
Perhaps the future will not be changed by one groundbreaking drug alone.
Perhaps it will also be changed by millions of conversations.
One mother who books an appointment because she recognised abnormal bleeding.
One young woman who accepts HPV vaccination because stigma was replaced with knowledge.
One survivor who discovers she is not alone.
One physician who chooses curiosity over assumption.
One consultation in which a patient finally feels safe enough to ask the question she has carried for months.
This is how cultures change.
This is how trust is built.
This is how prevention succeeds.
And perhaps, one day, this is how stigma disappears.
Because the true measure of progress in gynaecological oncology will not only be the number of lives we save.
It will also be the number of women who no longer feel they have to suffer in silence.
The Science Behind Stigma: An Underestimated Determinant of Health
Stigma is often perceived as an abstract social phenomenon—a matter of culture, perception or individual attitudes. In reality, it is increasingly recognised as a measurable determinant of health.
Over the past two decades, research across oncology, psychology and behavioural medicine has consistently demonstrated that stigma influences every stage of the cancer continuum. It affects whether symptoms are recognised, whether medical attention is sought promptly, whether treatment recommendations are followed and how patients adapt psychologically after diagnosis. In other words, stigma is not merely an emotional consequence of cancer. It actively shapes clinical outcomes.
This understanding challenges the traditional boundaries of oncology.
For decades, we have focused on biological determinants of disease: tumour stage, histological subtype, molecular alterations, immune response and genetic predisposition. These factors undoubtedly remain central to modern cancer care. Yet biology alone cannot explain why two patients with similar disease may experience profoundly different journeys.
Increasingly, evidence suggests that social determinants—including education, socioeconomic status, health literacy and stigma—interact with biological factors in ways that directly influence outcomes.
Gynaecological cancers provide one of the clearest examples of this interaction.
Unlike many other malignancies, these diseases affect organs that society continues to associate with sexuality, fertility, reproduction and femininity. Consequently, symptoms are frequently interpreted through emotional or cultural lenses long before they are understood medically.
Abnormal bleeding may be dismissed as hormonal imbalance.
Persistent bloating may be attributed to stress.
Vulvar symptoms are often self-treated because discussing them feels uncomfortable.
Women frequently normalise symptoms that should prompt urgent medical evaluation—not because they lack intelligence or concern for their health, but because embarrassment alters health-seeking behaviour.
Behavioural science has long recognised this phenomenon.
Health decisions are rarely driven by knowledge alone.
They are shaped by beliefs.
By previous experiences.
By cultural expectations.
By fear.
And perhaps most importantly, by anticipated judgement.
Many women do not delay seeking care because they underestimate the seriousness of their symptoms.
They delay because they overestimate the likelihood of being dismissed, misunderstood or embarrassed.
This distinction is critical.
It shifts our understanding of delayed diagnosis from one of individual responsibility to one of systemic responsibility.
If embarrassment prevents disclosure, then reducing embarrassment becomes part of prevention.
If stigma delays diagnosis, then combating stigma becomes a public health intervention.
This perspective has profound implications for gynaecological oncology.
As clinicians, we often encourage women to recognise symptoms earlier.
But recognition alone is insufficient.
Recognition must be accompanied by psychological safety—the confidence that seeking medical advice will be met with respect rather than judgement.
This is where healthcare systems play a pivotal role.
Every interaction with a patient either strengthens or weakens that confidence.
The receptionist who welcomes a woman without embarrassment.
The nurse who asks sensitive questions without assumptions.
The physician who discusses HPV without moral judgement.
The multidisciplinary team that acknowledges sexuality and fertility as legitimate medical concerns.
Together, these encounters shape a woman’s willingness to engage with healthcare not only today, but throughout her lifetime.
Stigma therefore extends beyond individual conversations.
It becomes embedded within healthcare structures, public discourse and societal expectations.
Importantly, stigma is not experienced equally by all women.
Young women diagnosed before completing their families often confront fears regarding fertility and identity.
Older women may assume that symptoms are simply “part of ageing.”
Women from minority populations or socially disadvantaged backgrounds frequently encounter additional barriers related to healthcare access, discrimination or limited health literacy.
Understanding these intersecting vulnerabilities is essential if we are to deliver genuinely equitable cancer care.
This broader perspective aligns closely with the contemporary concept of person-centred oncology.
The goal is no longer simply to classify tumours more accurately.
It is to understand patients more completely.
As oncology becomes increasingly personalised at the molecular level, it must become equally personalised at the human level.
The paradox of modern medicine is striking.
We can sequence an entire tumour genome within days.
Yet we may fail to ask a patient the one question that matters most:
“What has been your greatest fear since all of this began?”
Precision medicine has transformed our understanding of cancer biology.
The next frontier is precision communication.
Recognising which patient needs more reassurance.
Which patient needs more information.
Which patient is silently carrying shame.
Which patient simply needs permission to speak.
Because if stigma influences behaviour, and behaviour influences outcomes, then communication itself becomes an evidence-based intervention.
Not an optional addition to treatment.
But an integral component of high-quality cancer care.
The Hidden Second Diagnosis
For every woman diagnosed with a gynaecological cancer, there is the diagnosis recorded in her medical notes.
A histological subtype.
A FIGO stage.
A molecular profile.
A treatment plan.
These are the diagnoses we, as clinicians, are trained to recognise and treat.
But there is often another diagnosis.
One that never appears in pathology reports.
One that cannot be detected by imaging.
One that has no ICD code.
Yet it profoundly influences how many women experience cancer.
It is the diagnosis of stigma.
Unlike cancer, stigma does not arise from abnormal cellular growth.
It develops through silence, misconceptions, cultural expectations and social judgement.
It is rarely discussed during multidisciplinary tumour board meetings.
No international guideline includes a treatment algorithm for it.
No surgical procedure removes it.
Yet its consequences may accompany women long after chemotherapy has ended, scars have healed and surveillance visits become less frequent.
Perhaps this is why stigma deserves to be recognised as the hidden second diagnosis of gynaecological cancer.
Not because it replaces the biological disease.
But because it exists alongside it.
Every woman experiences this second diagnosis differently.
For one patient, it may appear as embarrassment when discussing abnormal vaginal bleeding.
For another, it emerges as guilt following an HPV diagnosis.
Some fear that cancer has diminished their femininity.
Others worry they are no longer desirable partners.
Many hesitate to discuss sexual dysfunction, infertility or menopausal symptoms because they assume these concerns are less important than surviving cancer itself.
Over time, this silent burden begins to shape behaviour.
Appointments are postponed.
Questions remain unasked.
Symptoms go unreported.
Emotional distress becomes normalised.
Isolation gradually replaces communication.
Unlike tumour progression, this process often occurs invisibly.
Yet its clinical consequences are real.
As physicians, we routinely classify tumours according to stage and biology because these factors determine treatment.
Perhaps modern oncology should become equally attentive to the invisible burdens patients carry alongside their disease.
Not because stigma can be measured as easily as tumour size.
But because it influences outcomes in ways we are only beginning to understand.
Recognising stigma as a second diagnosis changes our perspective.
Instead of asking only:
“How should we treat this cancer?”
we begin asking another question.
“What invisible burden is this woman carrying today?”
Sometimes the answer is fear.
Sometimes loneliness.
Sometimes uncertainty.
Sometimes shame.
Each requires a different conversation.
Each deserves the same attention we devote to laboratory results or imaging findings.
Because while medicine has become extraordinarily successful at treating disease, healing often begins only when we recognise the burdens that cannot be seen.
Cancer may begin in cells, but healing begins when a woman feels heard.
The future of gynaecological oncology will not be defined only by the cancers we cure, but by the women we empower. Scientific innovation will continue to transform diagnosis and treatment, but compassion, communication and dignity will always remain at the heart of excellent care. If we truly aspire to change the future of women’s cancer, we must do more than develop better therapies—we must create a world in which no woman feels ashamed to speak, afraid to ask, or alone in her journey. Because every conversation has the power to change a life. And sometimes, it saves one.
Reference
1. Akin-Odanye EO, Husman AJ. Impact of stigma and stigma-focused interventions on screening and treatment outcomes in cancer patients. ecancermedicalscience. 2021;15:1308.
2. Street RL Jr, Makoul G, Arora NK, Epstein RM. How does communication heal? Pathways linking clinician–patient communication to health outcomes. Patient Education and Counseling. 2009;74:295–301.
3. Epstein RM, Street RL Jr. Patient-Centered Communication in Cancer Care: Promoting Healing and Reducing Suffering. National Cancer Institute, NIH Publication No. 07-6225; 2007.
4. Donovan KA, et al. Sexual health in women after gynecologic cancer treatment: a review of prevalence, interventions and future directions. Gynecologic Oncology. 2021.
5. Carter J, Stabile C, Gunn A, Sonoda Y. The physical consequences of gynecologic cancer surgery and their impact on sexual, emotional and psychosocial well-being. Journal of Sexual Medicine. 2013.
6. ESGO Patient Advocacy Committee. Patient-centred care and survivorship recommendations.
7. Epstein RM, Street RL Jr. The values and value of patient-centred care. Annals of Family Medicine. 2011.
8. Back AL, Arnold RM, Tulsky JA. Mastering Communication with Seriously Ill Patients. Cambridge University Press.
9. Street RL Jr, Epstein RM. Key interpersonal functions and health outcomes in clinician–patient communication. Patient Education and Counseling.
10. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; 2020.
11. European Society of Gynaecological Oncology (ESGO). Strategic Plan and Patient Advocacy initiatives.
12. International Gynecologic Cancer Society (IGCS). Global curriculum and educational initiatives.
FIGO. Women’s Health and Cancer Control Strategies.
13. Akin-Odanye EO, Husman AJ. Impact of stigma and stigma-focused interventions on screening and treatment outcomes in cancer patients. ecancermedicalscience. 2021;15:1308
14. Else-Quest NM, et al. Cancer stigma, healthcare utilisation and psychological outcomes: current evidence and future directions. Psycho-Oncology.
15. Street RL Jr, Makoul G, Arora NK, Epstein RM. How does communication heal? Pathways linking clinician-patient communication to health outcomes. Patient Educ Couns. 2009;74:295–301.
16. Ernstmann N, et al. Patient-centred communication and patient-reported outcomes in oncology. Patient Education and Counseling.